Oculis (NASDAQ:OCS) Posts Quarterly Earnings Results, Misses Expectations By $0.28 EPS

Oculis (NASDAQ:OCS) issued its earnings results on Tuesday. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.28), Zacks reports. Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%.

Oculis Price Performance

Shares of OCS traded down $0.22 on Thursday, reaching $18.62. The stock had a trading volume of 19,762 shares, compared to its average volume of 44,952. The firm has a 50-day moving average of $20.86 and a 200 day moving average of $16.88. The firm has a market capitalization of $754.18 million, a PE ratio of -9.65 and a beta of 0.02. Oculis has a twelve month low of $10.55 and a twelve month high of $23.08. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01.

Analysts Set New Price Targets

OCS has been the topic of several recent analyst reports. HC Wainwright dropped their target price on Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research report on Thursday. Robert W. Baird increased their price objective on Oculis from $37.00 to $41.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, Chardan Capital reissued a “buy” rating and issued a $28.00 target price on shares of Oculis in a report on Thursday.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.